Substance / Medication

Alosetron

SNOMED 116509006 UMLS C0291772

Overview

Active Ingredient

alosetron

RxNorm CUI

85248

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Irritable colon

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

C reactive protein

LOINC 1988-5

secondary

Neutrophils

LOINC 770-8

secondary

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Study to Assess the Effect Of Alosetron On Mucosal Blood Flow

NCT00370032Phase 4Completed49 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

Rahimi Roja, Nikfar Shekoufeh, Abdollahi Mohammad · Clin Ther · 2008

PMID: 18555935Meta-Analysis

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Chang Lin, Chey William D, Harris Lucinda et al. · Am J Gastroenterol · 2006

PMID: 16606352Meta-Analysis

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Cremonini F, Delgado-Aros S, Camilleri M · Neurogastroenterol Motil · 2003

PMID: 12588472Meta-Analysis

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Cremonini F, Nicandro J P, Atkinson V et al. · Aliment Pharmacol Ther · 2012

PMID: 22779693RCTFull text (PMC)

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.

Olden Kevin W, Chey William D, Shringarpure Reshma et al. · Curr Med Res Opin · 2019

PMID: 30293448Observational

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause Richard, Ameen Vanessa, Gordon Susan H et al. · Am J Gastroenterol · 2007

PMID: 17509028Observational

The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.

Somers G I, Harris A J, Bayliss M K et al. · Xenobiotica · 2007

PMID: 17701832Observational

Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.

Kawano K, Mori T, Fu L et al. · Neurogastroenterol Motil · 2005

PMID: 15787949Observational

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.

Miller David P, Alfredson Tanya, Cook Suzanne F et al. · Am J Gastroenterol · 2003

PMID: 12809837Observational

Ischemic colitis during treatment with alosetron.

Friedel D, Thomas R, Fisher R S · Gastroenterology · 2001

PMID: 11159896Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Gastroenterology Physician

Internal Medicine — Gastroenterology

NUCC 207RG0100X

Find a Provider

Health Goals

Goals connected through associated conditions

Improve Gut Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Alosetron (substance)
SNOMED CT: 116509006
UMLS CUI: C0291772
RxNorm CUI: 85248

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.